Improvement in psoriasis during rituximab therapy for mixed cryoglobulinemia type II

Cutis. 2010 Sep;86(3):133-5.


Rituximab is a B-cell depleting monoclonal antibody targeting CD20. Data concerning the behavior of psoriatic disease following rituximab therapy are extremely limited. In this report, the clinical course of a patient with established psoriasis who received rituximab therapy for vasculitis associated with mixed cryoglobulinemia (MC) type II is described. In addition to marked improvement in MC manifestations, modest improvement in psoriatic lesions also was observed following therapy. The literature concerning B-cell depletion in the setting of psoriatic disease is briefly reviewed.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal, Murine-Derived / pharmacology
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use*
  • B-Lymphocytes / immunology
  • Cryoglobulinemia / complications
  • Cryoglobulinemia / drug therapy*
  • Humans
  • Immunologic Factors / pharmacology
  • Immunologic Factors / therapeutic use
  • Male
  • Middle Aged
  • Psoriasis / complications
  • Psoriasis / drug therapy*
  • Rituximab
  • Treatment Outcome
  • Vasculitis / drug therapy
  • Vasculitis / etiology


  • Antibodies, Monoclonal, Murine-Derived
  • Immunologic Factors
  • Rituximab